Institutional Investors Love Medicinova Inc (NASDAQ:MNOV)

December 8, 2017 - By Marie Mckinney

 Institutional Investors  Love Medicinova Inc (NASDAQ:MNOV)

Sentiment for Medicinova Inc (NASDAQ:MNOV)

Medicinova Inc (NASDAQ:MNOV) institutional sentiment increased to 1.46 in 2017 Q2. Its up 0.72, from 0.74 in 2017Q1. The ratio has increased, as 19 investment professionals increased and started new positions, while 13 reduced and sold their holdings in Medicinova Inc. The investment professionals in our partner’s database reported: 7.81 million shares, up from 7.58 million shares in 2017Q1. Also, the number of investment professionals holding Medicinova Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 2 Reduced: 11 Increased: 15 New Position: 4.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $248.73 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

The stock increased 2.68% or $0.18 during the last trading session, reaching $6.89. About 118,722 shares traded. MediciNova, Inc. (NASDAQ:MNOV) has declined 6.61% since December 8, 2016 and is downtrending. It has underperformed by 23.31% the S&P500.

Essex Woodlands Health Ventures Inc. holds 1.11% of its portfolio in MediciNova, Inc. for 1.17 million shares. Bridgeway Capital Management Inc owns 124,082 shares or 0.01% of their US portfolio. Moreover, American International Group Inc has 0% invested in the company for 20,301 shares. The Nebraska-based Ameritas Investment Partners Inc. has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 6,459 shares.#img1#

More notable recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Globenewswire.com which released: “MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation …” on November 01, 2017, also Globenewswire.com with their article: “MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase …” published on August 30, 2017, Globenewswire.com published: “MediciNova to Attend Mizuho Healthcare Conference in New York” on February 01, 2017. More interesting news about MediciNova, Inc. (NASDAQ:MNOV) were released by: Globenewswire.com and their article: “MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN …” published on December 07, 2017 as well as Globenewswire.com‘s news article titled: “MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for …” with publication date: April 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: